The deal will likely be structured. AS has plenty
Post# of 72440
(Total Views: 375)
Posted On: 02/23/2020 1:04:21 PM
The deal will likely be structured. AS has plenty of cash and will be able to make a compelling licensing offer since a large portion of the payout will be royalties and sales milestones (no risk or upfront burden).
Where AS might not be able to compete is a buyout scenario for all of Brilacidin or the whole company. A Pfizer could write a check for $500 million or more upfront. AS likely could not.
Where AS might not be able to compete is a buyout scenario for all of Brilacidin or the whole company. A Pfizer could write a check for $500 million or more upfront. AS likely could not.
(1)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼